SRTS Sensus Healthcare, Inc.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1494891 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-53.3%
TTM net income YoY-433.4%
TTM EPS YoY-438.9%
Revenue 3-yr CAGR-12.7%
Net income 3-yr CAGR—
Margins
Gross margin41.8%
Operating margin-74.0%
Net margin-96.5%
FCF margin-69.4%
EBITDA margin-71.9%
Returns
ROE-37.0%
ROA-32.4%
ROIC (approx.)-39.5%
Asset turnover0.34x
Leverage & solvency
Liabilities / assets12.6%
Debt / equity0.00x
Current ratio6.77x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.71x
Accruals ratio-9.5%
Payout ratio—
Capex / revenue1.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $27.48M | $41.81M |
| Cost of revenue | $15.62M | $17.38M |
| Gross profit | $11.87M | $24.43M |
| R&D expense | $7.78M | $4.22M |
| SG&A expense | $7.87M | $7.15M |
| Operating income | -$10.31M | $8.09M |
| Interest expense | — | -$932,000 |
| Pretax income | -$9.62M | $9.02M |
| Income tax | -$1.91M | $2.38M |
| Net income | -$7.72M | $6.65M |
| EBITDA | -$9.91M | $8.29M |
| EPS (basic) | -0.47 | 0.41 |
| EPS (diluted) | -0.47 | 0.41 |
| Weighted avg. shares (diluted) | 16.33M | 16.36M |
| Banking | ||
| Net interest income | $683,000 | $932,000 |
| Balance sheet | ||
| Cash & equivalents | $22.08M | $22.06M |
| Receivables | $6.04M | $19.73M |
| Inventory | $14.56M | $10.10M |
| Current assets | $45.89M | $56.74M |
| PP&E, net | $1.98M | $2.00M |
| Total assets | $53.04M | $62.16M |
| Current liabilities | $4.72M | $5.88M |
| Total liabilities | $4.94M | $6.34M |
| Shareholders' equity | $48.10M | $55.83M |
| Shares outstanding | 16.46M | 16.50M |
| Cash flow statement | ||
| Operating cash flow | $528,000 | -$831,000 |
| Capital expenditure | $196,000 | $276,000 |
| Free cash flow | $332,000 | -$1.11M |
| Investing cash flow | -$196,000 | -$276,000 |
| Financing cash flow | -$305,000 | $15,000 |
| Depreciation & amortization | $400,000 | $200,000 |
| Stock-based compensation | $295,000 | $323,000 |
| Share buybacks | $300,000 | — |
Free plan shows the latest 2 periods; Pro shows all 11 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.